STAT5A and breast cancer: Findings from the study conducted by Dr Rui’s group support the notion that STAT5A signaling is frequently absent during breast cancer progression and loss of nuclear phospho-Stat5 is associated with poor prognosis in node-negative breast cancer43,44.